The Signals Xynthetica solution brings AI-driven in-silico generation, predictive modeling, and experimental validation into a single, governed environment
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The companies aim to expand treatment options for millions living with metabolic disorders
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
Subscribe To Our Newsletter & Stay Updated
